Pascale Sinaï

Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium.

EcoPhos SA- a Belgian company focused on phosphate technology-has invented and developed innovative, economical and ecological processes applying to all market segments in the phosphates industry. The company was created in 1996 by Mr. Mohamed Takhim-the inventor-and VC Belgian firms to develop and commercialize new process breakthroughs in the chemistry of phosphate. The objective was to produce and purify phosphoric acid and phosphate salts. Since its foundation, EcoPhos has developed a unique modular technology platform. Various combinations of the EcoPhos modules are possible according to the available raw materials and the final required product for the phosphate industry. EcoPhos invested more than 30 million Eur for 10 years of technology development.

Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium.

CISSOID SA manufactures industrial voltage regulators, oscillators and related electrical equipment. It offers temperature semiconductor solutions, delivering standard products and custom solutions for power management, power conversion and signal conditioning in extreme temperature and harsh environments. The firm's products include enable energy, weight and cost savings in lighter, cooling-free and more compact electronic systems. The company was founded by Pierre Delatte, Demeus Laurent, Vincent Dessard and Denis Flandre in 2000 and is headquartered in Mont-Saint-Guibert, Belgium.

Solvay Pharmaceuticals SA develops, manufactures, and supplies pharmaceutical products. The company's products include cardio-metabolics, influenza vaccines, adjuvants, and women's and men's healthcare products. It offers fenofibrate, a cardio-metabolic product for treating raised blood lipids and dyslipidemia products that control cholesterol and triglycerides. The firm is headquartered in Brussels, France.

reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium.

Xylowatt SA designs, develops and builds gasification reactors for energy conversion from biomass and waste products. It offers NOTAR gasification reactor that produces syngas; and expert services. The company’s products convert energy from clean wood waste, contaminated wood, creosoted wood, radionuclides contaminated wood, agro residues, and sewage sludge. Its product is used in CHP and industrial applications. The company was founded in 2001 and it is headquartered in Charleroi, Belgium.

GreenWatt SA designs and installs on-site bio-methanization plants. It engages in the provision of renewable energy and recycling solutions for waste bio-methanization cogeneration. The company was founded by Marc-Jean Spiltoir, Patrick Alexandre Thierry Rene van den Broucke, and Therese Marie Wathelet Florence in 2004 and is headquartered in Louvain-la-Neuve, Belgium.

Centre d'Entreprise et d'Innovation de Louvain-La-Neuve NV provides advice and consultancy services for small and medium sized businesses. The firm is a launch base for start-ups and supports the created business during the first years of development. The company was founded on April 22, 2004 and is headquartered in Louvain-La-Neuve, Belgium.

PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium.

Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium.

Botalys SA engages in the development and operation of bioreactors to cultivate medicinal plants. It specializes in biotechnology, plant extract, hairy roots. The company was founded by Pierre-Antoine Mariage in 2011 and is headquartered in Ghislenghien, Belgium.

ViroVet NV is a Belgian company that focuses on the discovery, licensing, and development of biopharmaceutical products for livestock. The company is based in Leuven, Belgium. ViroVet was founded by Erwin Blomsma, Stefaan Wera, and Nesya Goris, with Erwin Blomsma serving as the CEO since incorporation.

Aphea.Bio SA engages in research and development of biotechnology and agricultural products. It develops next generation biopesticides and biostimulants based on natural microorganisms. The company was founded by Isabel Vercauteren and Steven Vandenabeele in December 5, 2016 and is headquartered in Ghent, Belgium.

Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium.

Pulsify Medical BV is a Belgian digital medical technology company that specializes in developing wearable ultrasound patches. The company is based in Louvain, Belgium. Pulsify Medical was founded in 2019 by Lieven Herbots, Xavier Rottenberg, Jan D'hooge, Steve Stoffels. Iwan van Vijfeijken has been the CEO of the company since 2019.